Henry Schein rises after BofA upgrades to 'buy'

Henry Schein

06/01/2025 14:49

** Shares of healthcare products distributor Henry Schein
 HSIC.O  rise ~4% to $71.94
    ** BofA Securities upgrades stock to "buy" from
"underperform"; raises price objective to $84 from $69
    ** HSIC stands out as a "best-of-breed dental asset" with a
proven ability to grow earnings at healthy rates, similar to its
performance before COVID-19, brokerage says
    ** Company is well-positioned to gain share from both
distributors and manufacturers due to its exposure to
high-growth dental service organizations (DSO) customers and
private label offerings - BofA Securities
    ** HSIC is positioned for long-term success with
"best-in-class portfolio in dental", with above-market exposure
to DSO customers - brokerage
    ** Six of 15 brokerages rate the stock "buy" or higher, 7
"hold" and 2 "sell"; median PT is $75 - data compiled by LSEG
    ** HSIC fell 8.6% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))